Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Characteristics of New Opioid Use Among Medicare Beneficiaries: Identifying High-Risk Patterns.

Raman SR, Bush C, Karmali RN, Greenblatt LH, Roberts AW, Skinner AC.

J Manag Care Spec Pharm. 2019 Sep;25(9):966-972. doi: 10.18553/jmcp.2019.25.9.966.

2.

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?

Wei AH, Roberts AW.

Cancer Discov. 2019 Aug;9(8):998-1000. doi: 10.1158/2159-8290.CD-19-0575.

PMID:
31371322
3.

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW.

Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24.

PMID:
31340982
4.

Domain swaps of Arabidopsis secondary wall cellulose synthases to elucidate their class specificity.

Hill JL Jr, Hill AN, Roberts AW, Haigler CH, Tien M.

Plant Direct. 2018 Jul 10;2(7):e00061. doi: 10.1002/pld3.61. eCollection 2018 Jul.

5.

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW.

Br J Haematol. 2019 Sep;186(6):e188-e191. doi: 10.1111/bjh.16069. Epub 2019 Jun 24. No abstract available.

PMID:
31234236
6.

Cas9+ conditionally-immortalized macrophages as a tool for bacterial pathogenesis and beyond.

Roberts AW, Popov LM, Mitchell G, Ching KL, Licht DJ, Golovkine G, Barton GM, Cox JS.

Elife. 2019 Jun 17;8. pii: e45957. doi: 10.7554/eLife.45957.

7.

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma.

Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I.

Haematologica. 2019 Jun 6. pii: haematol.2019.220590. doi: 10.3324/haematol.2019.220590. [Epub ahead of print]

8.

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, Blombery P, Lessene G, Majewski IJ, Thijssen R, Roberts AW, Huang DCS, Colman PM, Czabotar PE.

Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.

9.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

PMID:
31023700
10.

Convergent evolution of hetero-oligomeric cellulose synthesis complexes in mosses and seed plants.

Li X, Speicher TL, Dees DCT, Mansoori N, McManus JB, Tien M, Trindade LM, Wallace IS, Roberts AW.

Plant J. 2019 Sep;99(5):862-876. doi: 10.1111/tpj.14366. Epub 2019 May 25.

PMID:
31021018
11.

Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.

Naumann RB, Roberts AW, Marshall SW, Skinner AC.

Med Care. 2019 Mar;57(3):213-217. doi: 10.1097/MLR.0000000000001058.

PMID:
30629016
12.

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A.

Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004. Review.

PMID:
30537511
13.

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.

Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ.

Cancer Discov. 2019 Mar;9(3):354-369. doi: 10.1158/2159-8290.CD-18-1151. Epub 2018 Dec 5.

PMID:
30518523
14.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

PMID:
30514704
15.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
16.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
17.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25. Erratum in: Cancer Discov. 2019 Jul;9(7):980.

PMID:
30254093
18.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.

Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10.

19.

A Map of Toll-like Receptor Expression in the Intestinal Epithelium Reveals Distinct Spatial, Cell Type-Specific, and Temporal Patterns.

Price AE, Shamardani K, Lugo KA, Deguine J, Roberts AW, Lee BL, Barton GM.

Immunity. 2018 Sep 18;49(3):560-575.e6. doi: 10.1016/j.immuni.2018.07.016. Epub 2018 Aug 28.

PMID:
30170812
20.

Glycaemic management during the inpatient enteral feeding of people with stroke and diabetes.

Roberts AW, Penfold S; Joint British Diabetes Societies (JBDS) for Inpatient Care.

Diabet Med. 2018 Aug;35(8):1027-1036. doi: 10.1111/dme.13678.

PMID:
30152589
21.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ.

Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.

22.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

23.

Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.

Roberts AW, Saloner B, Dusetzina SB.

Psychiatr Serv. 2018 Jul 1;69(7):832-835. doi: 10.1176/appi.ps.201700315. Epub 2018 May 8.

24.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. Erratum in: J Clin Oncol. 2019 Sep 1;37(25):2299.

PMID:
29715056
25.

Functional Characterization of a Glycosyltransferase from the Moss Physcomitrella patens Involved in the Biosynthesis of a Novel Cell Wall Arabinoglucan.

Roberts AW, Lahnstein J, Hsieh YSY, Xing X, Yap K, Chaves AM, Scavuzzo-Duggan TR, Dimitroff G, Lonsdale A, Roberts E, Bulone V, Fincher GB, Doblin MS, Bacic A, Burton RA.

Plant Cell. 2018 Jun;30(6):1293-1308. doi: 10.1105/tpc.18.00082. Epub 2018 Apr 19.

26.

Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.

Roberts AW, Carpenter DM, Smith A, Look KA.

Res Social Adm Pharm. 2019 Feb;15(2):222-225. doi: 10.1016/j.sapharm.2018.04.002. Epub 2018 Apr 5.

PMID:
29650444
27.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

28.

Cellulose synthase 'class specific regions' are intrinsically disordered and functionally undifferentiated.

Scavuzzo-Duggan TR, Chaves AM, Singh A, Sethaphong L, Slabaugh E, Yingling YG, Haigler CH, Roberts AW.

J Integr Plant Biol. 2018 Jun;60(6):481-497. doi: 10.1111/jipb.12637. Epub 2018 Mar 30.

PMID:
29380536
29.

Direct observation of the effects of cellulose synthesis inhibitors using live cell imaging of Cellulose Synthase (CESA) in Physcomitrella patens.

Tran ML, McCarthy TW, Sun H, Wu SZ, Norris JH, Bezanilla M, Vidali L, Anderson CT, Roberts AW.

Sci Rep. 2018 Jan 15;8(1):735. doi: 10.1038/s41598-017-18994-4.

30.

Venetoclax: a primer.

Roberts AW.

Blood Adv. 2017 Feb 28;1(7):467. doi: 10.1182/bloodadvances.2017000547. eCollection 2017 Feb 28. No abstract available.

31.

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A.

Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16. No abstract available.

PMID:
29263442
32.

Tissue-Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells.

Roberts AW, Lee BL, Deguine J, John S, Shlomchik MJ, Barton GM.

Immunity. 2017 Nov 21;47(5):913-927.e6. doi: 10.1016/j.immuni.2017.10.006. Epub 2017 Nov 14.

33.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

34.

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.

Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A.

Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502.

PMID:
28782211
35.

Functional Specialization of Cellulose Synthase Isoforms in a Moss Shows Parallels with Seed Plants.

Norris JH, Li X, Huang S, Van de Meene AML, Tran ML, Killeavy E, Chaves AM, Mallon B, Mercure D, Tan HT, Burton RA, Doblin MS, Kim SH, Roberts AW.

Plant Physiol. 2017 Sep;175(1):210-222. doi: 10.1104/pp.17.00885. Epub 2017 Aug 2.

36.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770
37.

Targeting BCL-2-like Proteins to Kill Cancer Cells.

Cory S, Roberts AW, Colman PM, Adams JM.

Trends Cancer. 2016 Aug;2(8):443-460. doi: 10.1016/j.trecan.2016.07.001. Epub 2016 Jul 30. Review.

PMID:
28741496
38.

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW.

Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4.

39.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group.

J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3.

PMID:
28368672
40.

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Roberts AW, Stilgenbauer S, Seymour JF, Huang DCS.

Clin Cancer Res. 2017 Aug 15;23(16):4527-4533. doi: 10.1158/1078-0432.CCR-16-0955. Epub 2017 Jan 18. Review.

41.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

42.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

43.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

PMID:
28076910
44.

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.

Roberts AW, Huang D.

Clin Pharmacol Ther. 2017 Jan;101(1):89-98. doi: 10.1002/cpt.553. Epub 2016 Nov 26. Review.

45.

Targeting apoptotic pathways to treat lymphoid malignancies.

Roberts AW.

Rinsho Ketsueki. 2016;57(10):2054-2058.

PMID:
27795514
46.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O.

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.

PMID:
27760111
47.

Lock-In Programs and the Opioid Epidemic: A Call for Evidence.

Roberts AW, Gellad WF, Skinner AC.

Am J Public Health. 2016 Nov;106(11):1918-1919. No abstract available.

48.

Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy.

Roberts AW, Farley JF, Holmes GM, Oramasionwu CU, Ringwalt C, Sleath B, Skinner AC.

Health Aff (Millwood). 2016 Oct 1;35(10):1884-1892.

PMID:
27702963
49.

Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells.

Ushiki T, Huntington ND, Glaser SP, Kiu H, Georgiou A, Zhang JG, Metcalf D, Nicola NA, Roberts AW, Alexander WS.

PLoS One. 2016 Sep 1;11(9):e0162111. doi: 10.1371/journal.pone.0162111. eCollection 2016.

50.

Reducing Opioid Misuse: Evaluation of a Medicaid Controlled Substance Lock-In Program.

Skinner AC, Ringwalt C, Naumann RB, Roberts AW, Moss LA, Sachdeva N, Weaver MA, Farley J.

J Pain. 2016 Nov;17(11):1150-1155. doi: 10.1016/j.jpain.2016.07.003. Epub 2016 Aug 4.

PMID:
27497767

Supplemental Content

Loading ...
Support Center